Drug Profile
Plecanatide - Bausch Health Companies
Alternative Names: GCRA; Guanilib; SP-304; TRULANCELatest Information Update: 02 Jun 2022
Price :
$50
*
At a glance
- Originator Callisto Pharmaceuticals
- Developer Bausch Health Companies; Shandong Luoxin Pharmaceutical; Synergy Pharmaceuticals Inc
- Class Anti-inflammatories; Irritable bowel syndrome therapies; Laxatives; Peptides
- Mechanism of Action Enterotoxin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Constipation; Irritable bowel syndrome
- Discontinued Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 18 Mar 2022 Phase-III clinical trials in Constipation in China (PO) (NCT05151328)
- 09 Dec 2021 Shandong Luoxin Pharmaceutical Group plans phase III trial in Constipation in China (PO, Tablet, Once daily) in December 2021 (NCT05151328)
- 15 Jan 2021 Cipher Pharmaceuticals receives arbitration award (with regards to breach of contract with Bausch Health Companies) for plecanatide in Canada